Cebix Incorporated Inks $30.9m Series C and Appoints President and CEO

Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, has secured a $30.9M Series B investment. Prior investors InterWest, Sofinnova Ventures and Thomas, McNerney & Partners all participated in the financing. The company has also appointed Dr. Joel Martin as president and CEO.

North AmericaUSBriefs